Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer to Lead Company’s Next Phase of Business Growth
2024年7月8日 - 8:00PM
ビジネスワイヤ(英語)
− Mr. Campione brings more than 25 years global
experience in successful development and commercialization of
diagnostic imaging agents and radiopharmaceuticals −
− Blue Earth Diagnostics co-founder and former
Chief Executive Officer David Gauden, D.Phil., appointed as
full-time Chief Executive Officer of sister company Blue Earth
Therapeutics −
− Executive appointments designed to optimize
growth and industry leadership for both Bracco companies −
Bracco and Blue Earth Diagnostics Ltd, a Bracco company and
recognized leader in the development and commercialization of
innovative PET radiopharmaceuticals, today announced the
appointment of Marco Campione as its new Chief Executive Officer
(CEO), reporting to Bracco Imaging CEO Fulvio Renoldi Bracco. Mr.
Campione also joins the Blue Earth Diagnostics Ltd Board of
Directors and will serve as Vice Chair of the Blue Earth
Diagnostics Inc. Board of Directors. Dr. David Gauden, a co-founder
of Blue Earth Diagnostics and with the Company since 2014, assumes
the role of full-time CEO of Bracco subsidiary Blue Earth
Therapeutics. The changes reflect a carefully planned strategy to
drive continued growth, development and opportunity for both
companies and Bracco.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240708534807/en/
Marco Campione, Chief Executive Officer,
Blue Earth Diagnostics, a Bracco company (Photo: Business Wire)
“I congratulate Marco Campione on this CEO appointment and we
look forward to drawing upon his strategic, operational and broad
general business expertise as we increase our global leadership
throughout the diagnostic radiopharmaceutical industry,” said
Fulvio Renoldi Bracco, CEO of Bracco Imaging. “Marco joins the
Bracco Group at a transformative point in our evolution, as the
company matures, broadens its horizons globally and expands its
commercial presence.”
Mr. Renoldi continued, “I also want to take this opportunity to
recognize the many contributions of David Gauden in advancing the
success of Blue Earth Diagnostics, and I wish him the best of
success in now leading Blue Earth Therapeutics as its full-time
CEO.”
“I am excited and honored to assume the role of CEO at Blue
Earth Diagnostics,” said Mr. Campione. “The Company is a recognized
leader throughout the nuclear medicine and oncology communities,
having a strong reputation grounded in successful innovation,
execution and dedicated service on behalf of patient health. I look
forward to applying my experience towards expanding availability of
the Company’s PET imaging products for prostate cancer, advancing
its development programs in PET neuro-oncology and solid tumors,
and in exploring additional opportunities and collaborations.”
Marco Campione brings more than 25 years of experience from GE
HealthCare, where he most recently served as Executive Director and
Global Head of Contrast Media, General Manager Pharmaceutical
Diagnostics North America and President GE HealthCare Inc.
About Blue Earth Diagnostics Blue Earth Diagnostics, an
indirect subsidiary of Bracco Imaging S.p.A., is a growing
international molecular imaging company focused on delivering
innovative, well-differentiated diagnostic solutions that inform
patient care. Formed in 2014, the Company’s success is driven by
its management expertise and supported by a demonstrated track
record of rapid development and commercialization of positron
emission tomography (PET) radiopharmaceuticals. Blue Earth
Diagnostics’ expanding oncology portfolio encompasses a variety of
disease states, including prostate cancer and neuro-oncology. Blue
Earth Diagnostics is committed to the timely development and
commercialization of precision radiopharmaceuticals for potential
use in imaging and therapy. For more information, please visit:
www.blueearthdiagnostics.com.
About Bracco Imaging Bracco Imaging S.p.A., part of the
Bracco Group, is a world-leading diagnostic imaging provider.
Headquartered in Milan, Italy, Bracco Imaging develops,
manufactures and markets diagnostic imaging agents and solutions.
It offers a product and solution portfolio for all key diagnostic
imaging modalities: X-ray imaging (including Computed
Tomography-CT, Interventional Radiology, and Cardiac
Catheterization), Magnetic Resonance Imaging (MRI), Contrast
Enhanced Ultrasound (CEUS), and Nuclear Medicine through
radioactive tracers and novel PET imaging agents to inform clinical
management and guide care for cancer patients in areas of unmet
medical need. Our continually evolving portfolio is completed by a
range of medical devices, advanced administration systems and
dose-management software. In 2019 Bracco Imaging enriched its
product portfolio by expanding the range of oncology nuclear
imaging solutions in the urology segment and other specialties with
the acquisition of Blue Earth Diagnostics. In 2021, Bracco Imaging
established Blue Earth Therapeutics as a separate, cutting-edge
biotechnology vehicle to develop radiopharmaceutical therapies.
Visit: www.braccoimaging.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240708534807/en/
For Blue Earth Diagnostics (U.S.) Priscilla Harlan Vice
President, Corporate Communications (M) (781) 799-7917
priscilla.harlan@blueearthdx.com
For Blue Earth Diagnostics (UK) Clare Gidley Associate
Director Marketing and Communications Tel: +44 (0)1865 784186
clare.gidley@blueearthdx.com
Media Sam Brown Inc. Mike Beyer (M) (312) 961-2502
mikebeyer@sambrown.com